Amphivena Therapeutics, Inc., a South San Francisco, CA-based clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, closed a $62m Series C financing.
The round was co-led by NanoDimension and Qiming Venture Partners USA, with participation from new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and insiders MPM Capital, funds managed by Tekla Capital Management LLC and Franklin Berger.
The company intends to use the funds to continue to advance its lead therapeutic candidate.
Led by Jeanmarie Guenot, Ph.D., Chief Executive Officer and President, and Peter Van Vlasselaer, Ph.D., Executive Chairman, Amphivena Therapeutics is an immuno-oncology company that is developing T cell engagers for cancer.
Its lead therapeutic candidate, AMV564, is a bivalent, bispecific CD33/CD3 T cell engager that selectively eliminates leukemic blasts and myeloid derived suppressor cells (MDSC), sparing normal myeloid cells (e.g., neutrophils and monocytes).
Amphivena has raised $88.5 M to date in Series A, B and C venture financings.